Chevy Chase Trust Holdings LLC Trims Stock Position in IDEXX Laboratories, Inc. $IDXX

Chevy Chase Trust Holdings LLC trimmed its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.9% in the third quarter, Holdings Channel reports. The fund owned 40,845 shares of the company’s stock after selling 1,636 shares during the period. Chevy Chase Trust Holdings LLC’s holdings in IDEXX Laboratories were worth $26,095,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. WealthCollab LLC acquired a new position in shares of IDEXX Laboratories in the second quarter valued at approximately $30,000. J.Safra Asset Management Corp acquired a new stake in shares of IDEXX Laboratories during the third quarter worth $31,000. Armstrong Advisory Group Inc. lifted its holdings in shares of IDEXX Laboratories by 55.9% during the third quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock worth $34,000 after purchasing an additional 19 shares during the period. Salomon & Ludwin LLC purchased a new position in IDEXX Laboratories in the 3rd quarter valued at $35,000. Finally, Greykasell Wealth Strategies Inc. purchased a new position in IDEXX Laboratories in the 3rd quarter valued at $35,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. Barclays dropped their price objective on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. BTIG Research lowered their target price on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a report on Tuesday, February 3rd. Piper Sandler dropped their price target on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research note on Monday, February 9th. Weiss Ratings cut shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, January 29th. Finally, Wall Street Zen downgraded shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Seven investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $783.33.

IDEXX Laboratories Stock Performance

NASDAQ:IDXX opened at $586.37 on Tuesday. The firm’s fifty day simple moving average is $656.25 and its 200-day simple moving average is $666.45. The company has a quick ratio of 0.90, a current ratio of 1.23 and a debt-to-equity ratio of 0.23. The stock has a market cap of $46.69 billion, a PE ratio of 44.86, a price-to-earnings-growth ratio of 3.48 and a beta of 1.66. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Monday, February 2nd. The company reported $2.92 earnings per share for the quarter, missing the consensus estimate of $2.93 by ($0.01). IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The company had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same quarter in the previous year, the company posted $2.53 earnings per share. The company’s quarterly revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Insider Buying and Selling at IDEXX Laboratories

In related news, Director Sophie V. Vandebroek sold 1,464 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $628.62, for a total value of $920,299.68. Following the sale, the director owned 648 shares in the company, valued at $407,345.76. This represents a 69.32% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Jonathan Jay Mazelsky sold 23,326 shares of the firm’s stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $657.55, for a total value of $15,338,011.30. Following the completion of the transaction, the chief executive officer directly owned 83,606 shares of the company’s stock, valued at $54,975,125.30. The trade was a 21.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 45,957 shares of company stock worth $29,862,109. Corporate insiders own 0.98% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.